May 4 (Reuters) - Regulus Therapeutics Inc
* Regulus reports first quarter 2017 financial results and corporate restructuring
* Q1 loss per share $0.38
* Q1 revenue $100,000 versus $500,000
* Q1 revenue view $944,000 -- Thomson Reuters I/B/E/S
* Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S
* Regulus Therapeutics Inc says Paul Grint, president and CEO, to resign
* Regulus Therapeutics Inc - Announced a corporate restructuring plan to streamline its operations
* Regulus Therapeutics Inc says to restructure operations accompanied by a workforce reduction
* Says cutting workforce by about 30 percent
* Regulus Therapeutics Inc - Restructuring includes an immediate workforce reduction of approximately 30%
* Regulus Therapeutics Inc says restructuring expected to result in approximately $6.0 million in annual savings after one-time restructuring costs
* Regulus Therapeutics Inc - Promoted Daniel R. Chevallard to position of chief financial officer, effective immediately
* Regulus Therapeutics Inc says Jay Hagan to succeed Paul Grint as CEO Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.